Voxzogo 0.56mg Kit
NDC 68135-119
Product Information
Voxzogo 0.56mg (vosoritide) is a NDA-approved product labeled by Biomarin Pharmaceutical Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a white kit. This product entry covers the primary NDC 68135-119 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 68135-119?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- VOSORITIDE (UNII: 7SE5582Q2P)
- VOSORITIDE (UNII: 7SE5582Q2P) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2586364 - vosoritide 0.4 MG Injection
- RxCUI: 2586369 - VOXZOGO 0.4 MG Injection
- RxCUI: 2586369 - vosoritide 0.4 MG Injection [Voxzogo]
- RxCUI: 2586369 - Voxzogo 0.4 MG Injection
- RxCUI: 2586371 - vosoritide 0.56 MG Injection
* Please review the full disclaimer at the bottom of this page.
Patient Education
Vosoritide
Vosoritide is used to increase linear growth (height) in certain children 5 years of age or older who have achondroplasia (ACH; achondroplastic dwarfism; a genetic condition of bone growth that results in short arms and legs). Vosoritide is in a class of medications called C type natriuretic peptide (CNP) analogs. It works by increasing cartilage cell growth which results in increased bone growth.
[Learn More]
* Please review the full disclaimer at the bottom of this page.